Pasithea Therapeutics Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $18.0M
- Price
- $0.5394
- % Change (Daily % change from the live per-ticker quote feed.)
- +14.77%
- Volume
- 302.7K
About
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Quick stats
Quick-stats data pending — refreshes nightly.
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001841330
Websitehttps://www.pasithea.com
AI Summary
AI-generated1/5
minorneutralclinical trial
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Pasithea Therapeutics announced that an abstract for its Phase 1 dose-escalation study of PAS-004 in advanced solid tumors has been accepted for poster presentation at the ESMO Congress 2026.
The presentation, scheduled for October 23, 2026, will cover safety and pharmacokinetics of the macrocyclic MEK inhibitor in patients with MAPK pathway-driven tumors.
The company stated that the full abstract will be published on the ESMO website per the standard embargo schedule and that a follow-up release with detailed results is planned for the presentation date.